Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.

Capricor Therapeutics, Inc. (CAPR) is scheduled to announce Q2 earnings results on Wednesday, August 13th, after market close. The consensus EPS Estimate is -$0 ...

The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for ...

BACK TO CBER — Dr. Vinay Prasad has returned to the FDA’s Center for Biologics Evaluation and Research, leaving industry and ...

Despite zero revenue and increased losses, Capricor Therapeutics Inc (CAPR) focuses on strategic initiatives and regulatory ...

The shares of biotech companies fell after news that ousted regulator Vinay Prasad is set to go back to the US Food and Drug Administration. Prasad had previously overruled his own scientific review ...

Capricor Therapeutics Inc. CAPR) on Monday reported a loss of $25.9 million in its second quarter. On a per-share basis, the ...

Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit ...

NEW YORK - August 12, 2025 ( NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.

At 05:45 a.m. ET, Dow E-minis were up 98 points, or 0.22%, with 7,922 contracts changing hands, S&P 500 E-minis were up 6.25 ...

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration ...